Relationship between serum apelin -36 with mother's anthropometric indices at 18-24 months postpartum: a nested case- control study

Document Type : Original Article

Authors

1 Instructor, Department of Nursing, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

2 Assistant professor, Department of Midwifery and Reproductive Health, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

3 Instructor, Department of Nursing, Esfarayen School of Medical Sciences, Esfarayen, Iran. Reproductive Health & Midwifery Department, Medical Sciences Faculty, Tarbiat Modares University, Tehran, Iran.

Abstract

Introduction: The presence of apelin in hypothalamus indicates the potential role of this hormone in the balance of energy and food intake. According to apelin’s protective role on obesity, this study was performed with aim to investigate the relationship between serum apelin-36 with mother's anthropometric indices at 18-24 months postpartum.
Methods: In this nested case-control study, serum apelin-36 levels of 42 pregnant women was measured during 28-32 weeks of gestation and the first 24 hours after delivery using ELISA in 2014-2016. After delivery, the participants were divided in to two subgroups based on mode of delivery; vaginal delivery group and cesarean section group. Anthropometric indices were measured two times; third trimester of pregnancy and then 18-24 months after delivery. Data were analyzed by SPSS software (version 21) and independent t and paired t-test, Chi-square, regression, and Pearson correlation test. P<0.05 was considered significant.
 Results: Mean of serum apelin-36 level after vaginal delivery had a nearly significant reduction compared with third trimester of pregnancy (P=0.05). Serum level of apelin-36 after cesarean delivery had negative significant relationship with BMI (P = 0.007, r = -0.57) and waist circumference (P = 0.003, r = -0.62) at postpartum follow-up. Linear regression analysis revealed that serum apelin-36 after caesarian delivery was a significant independent predictors of BMI at postpartum follow-up (P< 0.01). Apelin-36 had no significant relationship with anthropometric parameters in vaginal delivery group (P> 0.05). There was no significant difference in mean of anthropometric indices between two groups including: total pregnancy weight gain (P = 0.51), third trimester BMI (P = 0.11), BMI (P = 0.19), waist circumference (P = 0.21), systolic (P = 0.22) and diastolic blood pressure (P = 0.34), weight retention (P = 0.37) at postpartum follow-up.
Conclusion: Maternal serum apelin-36 level had negative significant relationship with maternal body mass index and waist circumference in cesarean section group. However, this mechanism is not completely known.

Keywords

References

  1. Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care 2016; 22(7 Suppl):s176-85.
  2. Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol Sci 2015; 36(7):461-70.
  3. Saber A, Tehranian N, Pourali RS, Esmailzade MS. Role of Visfatin in Fertility and Reproduction: A Review Study. Journal of Sabzevar University of Medical Sciences 2019; 25(6): 829-44.
  4. Mashhad Taraqi AS, Tehranian N, Roudbaneh SP, Esmaeilzadeh MS, Kazemnejad A, Aghoozi MF, et al. Visfatin as a predictor for growth of fetus and infant. Turk J Obstet Gynecol 2018; 15(2):80-86.
  5. Saber A, Tehranian N, Esmailzade MS, Pourali Roudbaneh S. Relationship between Serum visfatin with anthropometric indices and maternal gestational weight gain. Iran J Obstet Gynecol Infertil 2019; 22(5):43-51.
  6. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulinsensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005; 102(30):10610-5.
  7. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251(2):471-6.
  8. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000; 74(1):34-41.
  9. Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem 2000; 275(28):21061-7.
  10. Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, Hinuma S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 2001; 1538(2-3):162-71.
  11. Sinen O, BÜLBÜL M, İzgüt-Uysal N. Peripheral Apelin Inhibits Gastrointestinal Motor Functions via CCK-dependent Pathway. The FASEB Journal 2016 Apr;30(1_supplement): pp.lb692-lb692.
  12. Tasci I, Dogru T, Naharci I, Erdem G, Yilmaz MI, Sonmez A, et al. Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes 2007; 115(7):428-32.
  13. Wei L, Hou X, Tatemoto K. Regulation of apelin mRNA expression by insulin and glucocorticoids in mouse 3T3-L1 adipocytes. Regul Pept 2005; 132(1-3):27-32.
  14. Edinger AL, Hoffman TL, Sharron M, Lee B, Yi Y, Choe W, et al. An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 1998; 72(10):7934-40.
  15. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92(3):347-55.
  16. Wysocka MB, Pietraszek-Gremplewicz K, Nowak D. The role of apelin in cardiovascular diseases, obesity and cancer. Front Physiol 2018; 9:557.
  17. Masri B, Knibiehler B, Audigier Y. Apelin signalling: a promising pathway from cloning to pharmacology. Cell Signal 2005; 17(4):415-26.
  18. Rayalam S, Della-Fera MA, Krieg PA, Cox CM, Robins A, Baile CA. A putative role for apelin in the etiology of obesity. Biochem Biophys Res Commun 2008; 368(3):815-9.
  19. Xu S, Tsao PS, Yue P. Apelin and insulin resistance: another arrow for the quiver? J Diabetes 2011; 3(3):225-31.
  20. Hehir MP, Morrison JJ. The adipokine apelin and human uterine contractility. Am J Obstet Gynecol 2012; 206(4):359.e1-5.
  21. Azaïs H, Leroy A, Ghesquiere L, Deruelle P, Hanssens S. Effects of adipokines and obesity on uterine contractility. Cytokine Growth Factor Rev 2017; 34:59-66.
  22. Yu XH, Tang ZB, Liu LJ, Qian H, Tang SL, Zhang DW, et al. Apelin and its receptor APJ in cardiovascular diseases. Clin Chim Acta 2014; 428:1-8.
  23. Houben ML, Nikkels PG, van Bleek GM, Visser GH, Rovers MM, Kessel H, et al. The association between intrauterine inflammation and spontaneous vaginal delivery at term: a cross-sectional study. PLoS One 2009; 4(8):e6572.
  24. Unal ER, Cierny JT, Roedner C, Newman R, Goetzl L. Maternal inflammation in spontaneous term labor. Am J Obstet Gynecol 2011; 204(3):223.e1-5.
  25. Neal JL, Lamp JM, Lowe NK, Gillespie SL, Sinnott LT, McCarthy DO. Differences in inflammatory markers between nulliparous women admitted to hospitals in preactive vs active labor. Am J Obstet Gynecol 2015; 212(1):68.e1-68.e8.
  26. Habata Y, Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Hinuma S, et al. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim Biophys Acta 1999; 1452(1):25-35.
  27. Sunter D, Hewson AK, and Dickson SL. Intracerebroventricular injection of apelin-13 reduces food intake in the rat. Neurosci Lett 2003; 353(1):1-4.
  28. Than A, Cheng Y, Foh LC, Leow MK, Lim SC, Chuah YJ, et al. Apelin inhibits adipogenesis and lipolysis through distinct molecular pathways. Mol Cell Endocrinol 2012; 362(1-2):227-41.
  29. Heinonen MV, Purhonen AK, Miettinen P, Pääkkönen M, Pirinen E, Alhava E, et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept 2005; 130(1-2):7-13.
  30. Castan-Laurell I, Vítkova M, Daviaud D, Dray C, Kováčiková M, Kovacova Z, et al. Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol 2008; 158(6):905-10.
  31. Heinonen MV, Laaksonen DE, Karhu T, Karhunen L, Laitinen T, Kainulainen S, et al. Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis 2009; 19(9):626-33.
  32. Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006; 114(10):544-8
  33. Boucher J, Masri B, Daviaud D, Gesta S, Guigné C, Mazzucotelli A, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146(4):1764-71.
  34. Taheri S, Murphy K, Cohen M, Sujkovic E, Kennedy A, Dhillo W, et al. The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun 2002; 291(5):1208-12.
  35. Bełtowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?. Med Sci Monit 2006; 12(6):RA112-119.
  36. Than A, He HL, Chua SH, Xu D, Sun L, Leow MK, et al. Apelin enhances brown adipogenesis and browning of white adipocytes. J Biol Chem 2015; 290(23):14679-91.
  37. Schwartz GJ, Moran TH. CCK elicits and modulates vagal afferent activity arising from gastric and duodenal sites. Ann N Y Acad Sci 1994; 713:121-8.
  38. He Q, Gao Z, Yin J, Zhang J, Yun Z, Ye J. Regulation of HIF-1α activity in adipose tissue by obesity-associated factors: adipogenesis, insulin, and hypoxia. Am J Physiol Endocrinol Metab 2011; 300(5):E877-85.

The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 23, Issue 1
March 2020
Pages 48-57

Files

Share

How to cite

Statistics